What to Know About This Fund's $6.6 Million UroGen Sale After a 600% Stock Surge This biotech firm develops therapies for urothelial cancers, leveraging proprietary delivery technology and a growing clinical pipeline.
Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally Vir Biotechnology develops immunology-based therapies targeting infectious diseases through global partnerships and scientific innovation.
As Terns Stock Soars 1,400%, What Does One Fund's $5.2 Million Sale Signal to Investors? This clinical-stage biotech develops therapies for NASH and obesity, advancing a pipeline of proprietary small-molecule drug candidates.
This New $7 Million Bet Targets a CNS Drug Maker With Phase 3 Trial Underway and 27% Stock Gain Axsome Therapeutics develops therapies for central nervous system disorders, with a late-stage pipeline targeting major unmet medical needs.
Sionna Stock Is Up 144% This Past Year. Is the Biotech a Buy as One Fund Makes a $7 Million Bet? This clinical-stage biotech develops therapies targeting the root cause of cystic fibrosis, with a pipeline focused on CFTR modulators.
This $6 Million Bet Adds a Brain Health Biotech to Portfolio Dominated by Clinical Stage Names This clinical-stage biopharma targets neurological and psychiatric disorders with a pipeline of novel therapeutics advancing through trials.
Billionaire Family Office Dumps All of Its UroGen Stock Amid 100% Rally A full exit after a monster rally says less about the company’s science and more about how disciplined funds lock in wins when portfolio math starts to matter.
UROGEN PHARMA LTD (NASDAQ:URGN) Reports Q3 2025 Earnings: Revenue Misses, Loss Per Share Beats UroGen Q3 2025 results show a revenue miss but a narrower-than-expected loss. The biopharma highlighted strong pipeline progress and the ongoing launch of its new product, ZUSDURI.
UROGEN PHARMA LTD (NASDAQ:URGN) Reports Mixed Q2 2025 Earnings Amid Widening Losses and Revenue Beat UroGen Pharma (URGN) reported Q2 2025 revenue of $24.2M, beating estimates, but EPS missed at -$1.05. JELMYTO sales grew 11% YoY, while ZUSDURI launch and R&D costs widened losses. Shares dipped pre-market.
3 Bullish Biotech Stocks With Explosive Growth Trends These small-cap biotech stocks offer high-reward potential with bullish momentum and key catalysts ahead in urology, autoimmune, and gene editing therapies
UroGen Pharma Stock Scores Bullish Price Target Revisions Up To $47 Following FDA Nod For Zusduri UroGen Pharma shares rallied to a three-month high after the FDA approved Zusduri, a non-surgical treatment for a type of bladder cancer.
Why UroGen Pharma (URGN) Stock Is Skyrocketing This Week UroGen Pharma shares are surging this week after the company gained FDA approval for ZUSDURI. The positive clinical trial results and an analyst upgrade fueled a significant stock price increase.
